OverviewSuggest Edit

Biostage is a biotechnology company developing bio engineered organ implants based on its novel Cellframe technology. The Company's Cellframe technology is comprised of a biocompatible scaffold seeded with the patient’s own stem cells. Biostage is pursuing the Cellspan esophageal implant as its first product candidate to address esophageal atresia and esophageal cancer and is also developing its technology’s applications to address conditions of the bronchus and trachea. 

TypePublic
Founded2012
HQHolliston, US
Websitebiostage.com

Latest Updates

Employees (est.) (Sept 2019)14
Revenue (FY, 2019)$0
Share Price (Sept 2020)$1.5 (-13%)
Cybersecurity ratingAMore

Key People/Management at Biostage

Jim McGorry

Jim McGorry

President & CEO
Hong Yu

Hong Yu

President
Shunfu Hu

Shunfu Hu

VP of Business Development and Operations
William Fodor

William Fodor

Chief Scientific Officer
Sumati Sundaram

Sumati Sundaram

Director of Cell Biology
Jeff Bouchard

Jeff Bouchard

Director of Engineering, Manufacturing and Quality
Show more

Biostage Office Locations

Biostage has an office in Holliston
Holliston, US (HQ)
84 October Hill Rd
Show all (1)

Biostage Financials and Metrics

Biostage Revenue

USD

Net income (Q2, 2020)

(1.2m)

EBIT (Q2, 2020)

(1.3m)

Market capitalization (22-Sept-2020)

13.2m

Closing stock price (22-Sept-2020)

1.5

Cash (30-Jun-2020)

618.0k

EV

13.3m
Biostage's current market capitalization is $13.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

22.0k93.0k118.0k82.0k

Revenue growth, %

323%27%(31%)

Cost of goods sold

11.0k48.0k139.0k116.0k

Gross profit

11.0k45.0k(21.0k)(34.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

23.0k23.0k2.0k73.0k37.0k28.0k26.0k

Cost of goods sold

12.0k12.0k1.0k37.0k18.0k44.0k13.0k

Gross profit

11.0k11.0k1.0k36.0k19.0k(16.0k)13.0k

Gross profit Margin, %

48%48%50%49%51%(57%)50%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

14.0m5.3m7.5m2.9m4.0m1.3m913.0k

Accounts Receivable

5.0k21.0k42.0k

Prepaid Expenses

421.0k317.0k330.0k289.0k623.0k444.0k

Inventories

38.0k207.0k75.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.6m10.1m7.7m12.2m10.1m8.2m4.8m8.1m6.0m6.6m3.4m1.3m2.8m5.8m3.5m1.1m1.3m1.1m806.0k618.0k

Accounts Receivable

29.0k81.0k59.0k18.0k40.0k66.0k37.0k

Prepaid Expenses

33.0k349.0k356.0k117.0k269.0k173.0k82.0k485.0k156.0k96.0k249.0k178.0k94.0k357.0k228.0k229.0k499.0k516.0k248.0k346.0k273.0k

Inventories

129.0k146.0k157.0k212.0k201.0k144.0k79.0k47.0k41.0k
Show all financial metrics

Biostage Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Biostage Online and Social Media Presence

Embed Graph

Biostage News and Updates

Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update

HOLLISTON, Mass., Aug. 7, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three...

Biostage Reports 2018 Third Quarter Financial Results

HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for ...

Ms. Ting Li Appointed to Biostage Board of Directors

HOLLISTON, Mass., Nov. 7, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today announced appointing Ms. Ting Li to its Board of Directors after ...

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

HOLLISTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has been awarded $1.1 million from Phase II of its...

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

HOLLISTON, Mass., Nov. 2, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three ...

Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Operations

HOLLISTON, Mass., Aug. 9, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three ...
Show more

Biostage Frequently Asked Questions

  • When was Biostage founded?

    Biostage was founded in 2012.

  • Who are Biostage key executives?

    Biostage's key executives are Jim McGorry, Hong Yu and Shunfu Hu.

  • How many employees does Biostage have?

    Biostage has 14 employees.

  • Who are Biostage competitors?

    Competitors of Biostage include Biovotion, Hemex Health and Garwood Medical Devices.

  • Where is Biostage headquarters?

    Biostage headquarters is located at 84 October Hill Rd, Holliston.

  • Where are Biostage offices?

    Biostage has an office in Holliston.

  • How many offices does Biostage have?

    Biostage has 1 office.